Circio Holding ASA

Pre-Annual General Meeting Information • May 27, 2025

Circio Holding ASA - Updated information to the notice of annual general meeting 2025 - Reverse share split and share capital decrease

Circio Holding ASA - Updated information to the notice of annual general meeting 2025 - Reverse share split and share capital decrease

Oslo, 27 May 2025: Reference is made to the notice of the annual general meeting

of Circio Holding ASA (the "Company") published on 15 May 2025 and the annual

general meeting ("AGM") to be held on Thursday 5 June 2025 at 10:00 hours

(CEST).

The board of directors has resolved to withdraw the proposals under agenda item

10 "Reverse Share Split" and agenda item 11 "Share Capital Decrease".

Consequently, agenda item 10 and agenda item 11 will not be subject to voting at

the AGM.

In addition, the board of directors proposes that the previously proposed board

authorizations in agenda items 12 "General board authorization to increase the

share capital" and agenda item 13 "Board authorization to increase the share

capital in connection with share incentive arrangements and grant of restricted

stock units to the board of directors as remuneration" are adjusted to reflect

the withdrawal of the reverse share split and the share capital decrease.

For agenda item 12, the board of directors proposes that it is granted an

authorization to increase the Company's share capital by up to either 40%

(agenda item 12.1), 30% (agenda item 12.2), or 20% (agenda item 12.3) of the

Company's share capital as of the date of the general meeting.

For agenda item 13, the board of directors proposes that it is granted an

authorisation to increase the Company's share capital by up to 10% of the

Company's share capital as at the date of the general meeting.

An updated AGM registration and proxy form is attached to this announcement and

is available for advance voting through the logging on to VPS Investor Services,

by following link on the Company's webpage https://www.circio.com/en/annual

-general-meeting-2025/. Please note that any advance votes cast on the items

under agenda item 10 and agenda item 11 will be considered void. Any advance

votes cast on agenda item 12 and 13 can be changed up until the applicable

voting deadlines as given in the notice.

For further information, please contact:

Erik Digman Wiklund, CEO

Phone: +47 413 33 536

Email: erik.wiklund@circio.com

Lubor Gaal, CFO

Phone: +34 683343811

Email: lubor.gaal@circio.com

About Circio

Building next generation RNA technology for nucleic acid medicine

Circio Holding ASA is a biotechnology company developing powerful circular RNA

vector expression technology for next generation nucleic acid medicine.

Circio has established a unique circular RNA (circRNA) vector expression

platform for novel DNA, RNA and viral therapeutics. The proprietary circVec

technology is based on a modular genetic cassette design for efficient

biogenesis of multifunctional circRNA inside cells, which can be deployed in

multiple therapeutic settings, including genetic medicine, cell therapy and

chronic disease. The circVec platform has demonstrated up to 15-fold enhanced

and more significantly more durable protein expression vs. classic mRNA vector

systems and has the potential to become a new gold-standard platform technology

for nucleic acid and viral therapeutics in the future. The circRNA R&D

activities are being conducted by the wholly owned subsidiary Circio AB based at

the Karolinska Institute in Stockholm, Sweden.

In addition, Circio is developing a pan-RAS cancer vaccine, TG01, targeting KRAS

driver mutations. TG01 is currently being tested in two clinical trials: RAS

-mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway.

These studies are being run through academic and industry collaborative

networks, supported by prestigious research grants from Innovation Norway and

the Norwegian Research Council, creating read-outs and future optionality for

the program at low cost to Circio.